Comparative Benchmarking
In the context of the broader market, RGNT competes directly with industry leaders such as ELAB and PHGE. With a market capitalization of $12.48M, it holds a leading position in the sector. When comparing efficiency, RGNT's gross margin of N/A stands against ELAB's 10.42% and PHGE's N/A. Such benchmarking helps identify whether Regentis Biomaterials Ltd is trading at a premium or discount relative to its financial performance.
